The COVID-19 pandemic has led to an increase in investments in digital transformation and emerging technologies to deal with the shift towards remote working and mobility restrictions.
Pre-clinical and clinical trial processes likely to benefit most from digital transformation: Survey
Declining profit margins and increasing costs have prompted the pharmaceutical industry to expedite digital transformation to adopt to the changing business environment.
Larger and small companies have increased their focus on the prospect of innovating and enabling operations through digital transformation in 2020 following the COVID-19 pandemic.
The COVID-19 pandemic has accelerated the adoption of digital strategies in the pharmaceutical industry as several companies have started exploring emerging technologies in business settings.
The use of digital technologies in clinical trials in the last decade has increased exponentially, according to data from GlobalData’s pharmaceutical, medical devices and clinical trials databases.
Digital transformation has been one of the key strategic initiatives being undertaken by the pharmaceutical industry in recent years. The shift towards digital transformation has gained more importance following the COVID-19 pandemic.